-
Consider the “whole-man” when treating prostate cancer
-Healthcare professionals need to consider the impact of prostate cancer on the ‘whole man’ rather than focusing on cancer treatment in isolation, according to results from an international survey of prostate cancer patients and their partners…
-
Wake Up to Nocturia Studies Reinforce Serious Associated Risk of Nocturia
-Study results discussed today at the European Association of Urology (EAU) Congress in Barcelona, have reinforced the association between nocturia and a greater risk of falls and mortality…
-
Xanodyne and Ferring announce co-promote for ZIPSOR™
-Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management…
-
FIRMAGON® has a significantly greater probability of PSA recurrence-free survival than leuprolide in prostate cancer patients
-Results from a phase III pivotal study sub-analyses reported in European Urology show that…
-
Launch of FIRMAGON
-Launch of FIRMAGON® (degarelix), a GnRH blocker for advanced hormone-dependent prostate cancer.
0 -
Ferring donates $3 million to the Royal Textile Academy of Bhutan
-Frederik Paulsen, Chairman, Ferring Pharmaceuticals, announced a $3 million donation to the Royal Textile Academy of Bhutan…
-
Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) 2010 Theme Announced
-Ferring Pharmaceuticals is proud to announce the second Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) today…
-
New Data Supports Significant Economic and Clinical Value of MENOPUR® in IVF
-New data from an economic analysis presented today at this year’s European Society of Human Reproduction and Embryology (ESHRE) congress showed that…
-
Ferring launches New International Fertility Media Award (FIMA) 2010
-Ferring is proud to announce the launch of its first Fertility Media Award (FIMA) today during the 25th Annual Society of Human Reproduction and Embryology (ESHRE) congress…
-
Ferring Pharmaceuticals announces new Board Member
-Ferring Pharmaceuticals announced today that Dr. John Patterson CBE FRCP has been appointed as a new Board Member with immediate effect…
Uncategorized
Uncategorized